| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month from now) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month from now) | |
| US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month from now) | |
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(a month from now) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(a month from now) | |
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(1 year, 1 month from now) | |
| US8741904 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 10 months from now) | |
| US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7605240 | SALIX PHARMS | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
Aug, 2019
(4 years ago) | |
| US7718608 | SALIX PHARMS | Methods of treating a subject suffering from irritable bowel syndrome |
Aug, 2019
(4 years ago) | |
| US6861053 | SALIX PHARMS | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(4 years ago) | |
| US7935799 | SALIX PHARMS | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
Aug, 2019
(4 years ago) | |
| US7452857 | SALIX PHARMS | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(4 years ago) | |
| US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(a month from now) | |
| US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(a month from now) | |
| US7915275 | SALIX PHARMS | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(9 months from now) | |
| US9271968 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 10 months from now) | |
| US10703763 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 10 months from now) | |
| US8518949 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 10 months from now) | |
| US11779571 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(4 years from now) | |
| US11564912 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(4 years from now) | |
| US10456384 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(4 years from now) | |
| US10765667 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(4 years from now) | |
| US8309569 | SALIX PHARMS | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(5 years from now) | |
| US9629828 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
| US10709694 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
| US10335397 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
| US8829017 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
| US9421195 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
| US8946252 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
| US7928115 | SALIX PHARMS | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
| US10314828 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(5 years from now) | |
| US8642573 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(5 years from now) | |
| US8969398 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(5 years from now) | |
Xifaxan is owned by Salix Pharms.
Xifaxan contains Rifaximin.
Xifaxan has a total of 34 drug patents out of which 5 drug patents have expired.
Expired drug patents of Xifaxan are:
- US7605240
- US7718608
- US6861053
- US7935799
- US7452857
Xifaxan was authorised for market use on 24 March, 2010.
Xifaxan is available in tablet;oral dosage forms.
Xifaxan can be used as reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode, treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof., treatment of irritable bowel syndrome with diarrhea (ibs-d) in adult female subjects, treatment of patients with hepatic encephalopathy (he), treatment of bloating associated with diarrhea-predominant irritable bowel syndrome (ibs-d) in adult female subjects, reduction in risk of overt hepatic encephalopathy (he) recurrence, treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older, reduction in risk of overt hepatic encephalopathy (he) in adults, method of treating travelers' diarrhea, treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults., treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof, treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older.
The generics of Xifaxan are possible to be released after 02 October, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-709) | May 27, 2018 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Product(NP) | Mar 24, 2013 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Treatment of travelers' diarrhea (t...
Dosage: TABLET;ORAL
XIFAXAN family patents
